Factors affecting survival after palliative radiotherapy in patients with lung cancer
Abstract
BACKGROUND: Lung cancer is the most common cancer worldwide. It is estimated that 60% of patients with NSCLC at time of diagnosis have advanced disease.
The aim of this study was to identify factors that play a major role in the survival of lung cancer patients treated with palliative radiotherapy.
MATERIALS AND METHODS: We retrospectively reviewed data of 280 lung cancer patients treated with palliative radiotherapy from January 2013 to December 2017. A multivariate analysis using the proportional hazards model of Cox was conducted. Also, Kaplan Meier curves were used to describe the distribution of survival times of the patients. The level of significance was set at 0.05.
RESULTS: The mean age at diagnosis was 65.6 years. About 77.5% of patients were male and 22.5% were female. In our cohort > 95% had stage 4 lung cancer. Most cases were adenocarcinomas (72.5%) and ECOG-PS 0-1 (80.4%). Different sites were submitted to palliative treatment: 120 brain metastases, 96 bone metastases, 53 lung tumour, 8 lymph nodes and 3 lung metastases.
Brain as first site of palliative radiotherapy (HR: 1.553, 95% CI: 1.167–2.067, p = 0.003) and ECOG-PS 2–3 compared with ECOG-PS 0–1 (HR: 2.253, 95% CI: 1.546–3.283, p ≤ 0.001) were associated with increased likelihood of lung cancer death. Patients who received biological therapy had 70.7% (p ≤ 0.001) reduction in lung cancer death risk.
CONCLUSION: Brain as the first metastatic site treated with radiotherapy and ECOG-PS 2–3 are associated with increased lung cancer death. Biological therapy was associated with decreased death risk.
Keywords: lung neoplasmsradiotherapypalliative therapy
References
- Carioli G, Bertuccio P, Boffetta P, et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol. 2020; 31(5): 650–658.
- Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020; 38(14): 1505–1517.
- Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22): 2078–2092.
- Nowicki A, Farbicka P, Krajnik M, et al. Palliative care in patients with lung cancer. Contemp Oncol (Pozn). 2013; 17(3): 238–245.
- Moumtzi D, Lampaki S, Zarogoulidis P, et al. Prognostic factors for long term survival in patients with advanced non-small cell lung cancer. Ann Transl Med. 2016; 4(9): 161.
- Lemjabbar-Alaoui H, Hassan OUi, Yang YW, et al. Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015; 1856(2): 189–210.
- Jumeau R, Vilotte F, Durham AD, et al. Current landscape of palliative radiotherapy for non-small-cell lung cancer. Transl Lung Cancer Res. 2019; 8(Suppl 2): S192–S201.
- Shamp S, Patel RB, Biswas T. Palliative Radiation Therapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Survival, Epidemiology and End Results (SEER) Analysis. Int J Radiat Oncol Biol Phys. 2017; 99(2): E495.
- Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017; 7(1): 4–12.
- De Felice F, Piccioli A, Musio D, et al. The role of radiation therapy in bone metastases management. Oncotarget. 2017; 8(15): 25691–25699.
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5): 1341–1346.
- Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014; 86(1): 78–84.
- Kawano D, Takeo S, Katsura M, et al. Surgical treatment of stage IV non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2012; 14(2): 167–170.
- Li J, Zhu H, Sun L, et al. Prognostic value of site-specific metastases in lung cancer: A population based study. J Cancer. 2019; 10(14): 3079–3086.
- Janssen S, Kaesmann L, Schild SE, et al. Impact of the Radiation Dose and Completion of Palliative Radiotherapy on Survival in Patients Treated for Locally Advanced Lung Cancer. Anticancer Res. 2016; 36(4): 1825–1828.
- Støchkel Frank M, Schou Nørøxe D, Nygård L, et al. When is referral of Heaf test positive schoolchildren worth while? Prospective study. BMJ. 1996; 313(7059): 726–727.
- Westhoff PG, de Graeff A, Monninkhof EM, et al. Dutch Bone Metastasis Study Group. Effectiveness and toxicity of conventional radiotherapy treatment for painful spinal metastases: a detailed course of side effects after opposing fields versus a single posterior field technique. J Radiat Oncol. 2018; 7(1): 17–26.
- Brown PD, Ahluwalia MS, Khan OH, et al. Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? J Clin Oncol. 2018; 36(5): 483–491.
- Nieder C, Tollali T, Yobuta R, et al. Palliative Thoracic Radiotherapy for Lung Cancer: What Is the Impact of Total Radiation Dose on Survival? J Clin Med Res. 2017; 9(6): 482–487.
- Moeller B, Balagamwala EH, Chen A, et al. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. Pract Radiat Oncol. 2018; 8(4): 245–250.
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10): 947–957.
- Rosell R, Carcereny E, Gervais R, et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3): 239–246.
- Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25): 2385–2394.
- Solomon BJ, Mok T, Kim DW, et al. PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23): 2167–2177.
- Shaw AT, Ou SHI, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21): 1963–1971.
- Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015; 33(9): 992–999.
- Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387(10027): 1540–1550.
- Rittmeyer A, Barlesi F, Waterkamp D, et al. OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389(10066): 255–265.